These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38990472)
1. Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. Garnier C; Schein M; Lacroix C; Jouve E; Soeiro T; Gentile G; Lapeyre Mestre M; Micallef J CNS Drugs; 2024 Sep; 38(9):743-751. PubMed ID: 38990472 [TBL] [Abstract][Full Text] [Related]
2. [Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network]. Modelon H; Frauger E; Laurenceau D; Thirion X; Mallaret M; Micallef J; Therapie; 2007; 62(4):337-46. PubMed ID: 17983559 [TBL] [Abstract][Full Text] [Related]
3. Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. Peyriere H; Eiden C; Micallef J; Lapeyre-Mestre M; Faillie JL; Blayac JP Eur Addict Res; 2013; 19(5):235-44. PubMed ID: 23428846 [TBL] [Abstract][Full Text] [Related]
4. [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network]. Frauger E; Pochard L; Boucherie Q; Giocanti A; Chevallier C; Daveluy A; Gibaja V; Caous AS; Eiden C; Authier N; Le Boisselier R; Guerlais M; Jouanjus É; Lepelley M; Pizzoglio V; Pain S; Richard N; Micallef J; Therapie; 2017 Sep; 72(4):491-501. PubMed ID: 28343650 [TBL] [Abstract][Full Text] [Related]
8. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Frauger E; Moracchini C; Le Boisselier R; Braunstein D; Thirion X; Micallef J; Fundam Clin Pharmacol; 2013 Dec; 27(6):672-82. PubMed ID: 23510229 [TBL] [Abstract][Full Text] [Related]
9. Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: Insights of the annual cross sectional OPPIDUM survey. Blayac L; Ponte C; Lavaud M; Micallef J; Lapeyre-Mestre M Therapie; 2023; 78(2):201-211. PubMed ID: 36283856 [TBL] [Abstract][Full Text] [Related]
10. [Uro- and nephrotoxic effects of drugs of abuse: Literature review and pharmaco-epidemiological survey in France and in the Marseille area]. Gully M; Frauger É; Spadari M; Pochard L; Pauly V; Romain F; Gondouin B; Sallée M; Moussi-Frances J; Burtey S; Dussol B; Daniel L; Micallef J; Jourde-Chiche N Nephrol Ther; 2017 Nov; 13(6):429-438. PubMed ID: 28958905 [TBL] [Abstract][Full Text] [Related]
11. [Analysis of addictive behaviours among new prisoners in France using the OPPIDUM program]. Pauly V; Frauger E; Rouby F; Sirere S; Monier S; Paulet C; Gibaga V; Micallef J; Thirion X Encephale; 2010 Apr; 36(2):122-31. PubMed ID: 20434629 [TBL] [Abstract][Full Text] [Related]
12. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Thirion X; Micallef J; Barrau K; Djezzar S; Sanmarco JL; Lagier G Eur Addict Res; 2001 Mar; 7(1):32-6. PubMed ID: 11316923 [TBL] [Abstract][Full Text] [Related]
13. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting]. Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408 [TBL] [Abstract][Full Text] [Related]
14. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Nordmann S; Frauger E; Pauly V; Orléans V; Pradel V; Mallaret M; Thirion X; Micallef J Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):184-90. PubMed ID: 22109894 [TBL] [Abstract][Full Text] [Related]
15. [On the risk of dependence on gabapentinoids]. Bonnet U; Scherbaum N Fortschr Neurol Psychiatr; 2018 Feb; 86(2):82-105. PubMed ID: 29179227 [TBL] [Abstract][Full Text] [Related]
16. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Driot D; Jouanjus E; Oustric S; Dupouy J; Lapeyre-Mestre M Br J Clin Pharmacol; 2019 Jun; 85(6):1260-1269. PubMed ID: 30737829 [TBL] [Abstract][Full Text] [Related]
17. Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance. Tambon M; Ponté C; Jouanjus E; Fouilhé N; Micallef J; Lapeyre-Mestre M; Front Psychiatry; 2021; 12():639780. PubMed ID: 33613345 [No Abstract] [Full Text] [Related]
18. Methamphetamine as the most common concomitant substance used with pregabalin misuse. Ovat DY; Aslan R; Kirli U; Akgür SA J Pharm Biomed Anal; 2024 Apr; 241():115996. PubMed ID: 38330785 [TBL] [Abstract][Full Text] [Related]
19. Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany. Snellgrove BJ; Steinert T; Jaeger S CNS Drugs; 2017 Oct; 31(10):891-898. PubMed ID: 28965335 [TBL] [Abstract][Full Text] [Related]
20. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Bossard JB; Ponté C; Dupouy J; Lapeyre-Mestre M; Jouanjus E Clin Drug Investig; 2016 Sep; 36(9):735-742. PubMed ID: 27300651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]